Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on August 9, 2022. The filing discloses a corporate governance change involving the appointment of a new Board member and Chair.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
The primary material change reported is the appointment of Dr. Jonathan Isaacsohn as a member and Chair of the Board of Directors, effective immediately on August 9, 2022. This appointment was made pursuant to a common stock and warrant purchase agreement dated July 22, 2022, between the Company, CinPax, LLC, and CinRx Pharma, LLC.
Management Commentary and Compensation
- Role: Dr. Isaacsohn serves as an independent director and Chair of the Board.
- Experience: He brings over 25 years of experience in clinical medicine and drug development, previously serving as Chief Medical Officer at Teva Pharmaceutical Industries Ltd. and currently as President and CEO of CinRx Pharma, LLC.
- Compensation:
- Annual cash payment: $70,000.
- Initial equity grant: 50,000 options upon appointment.
- Recurring equity grant: 50,000 options following each annual meeting of stockholders.
- Reimbursement for out-of-pocket expenses.
- Committees: As of the filing date, Dr. Isaacsohn has not been appointed to any specific Board committees.
Investor Verification Checklist
- Verify the terms of the common stock and warrant purchase agreement dated July 22, 2022, referenced as the basis for this appointment.
- Confirm the vesting schedule and exercise price for the 50,000 options granted to Dr. Isaacsohn.
- Review the standard director and executive officer indemnification agreement referenced in the filing.
- Monitor future filings for Dr. Isaacsohn's assignment to specific Board committees.